vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and EASTMAN KODAK CO (KODK). Click either name above to swap in a different company.
EASTMAN KODAK CO is the larger business by last-quarter revenue ($290.0M vs $191.2M, roughly 1.5× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 9.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 7.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
The Eastman Kodak Company, referred to simply as Kodak, is an American public company that produces various products related to its historic basis in film photography. The company is headquartered in Rochester, New York, and is incorporated in New Jersey. It is best known for photographic film products, which it brought to a mass market for the first time.
AXSM vs KODK — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $290.0M |
| Net Profit | — | $-108.0M |
| Gross Margin | — | 23.1% |
| Operating Margin | -33.1% | -0.3% |
| Net Margin | — | -37.2% |
| Revenue YoY | 57.4% | 9.0% |
| Net Profit YoY | — | -515.4% |
| EPS (diluted) | — | $-1.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $290.0M | ||
| Q3 25 | $171.0M | $269.0M | ||
| Q2 25 | $150.0M | $263.0M | ||
| Q1 25 | $121.5M | $247.0M | ||
| Q4 24 | $118.8M | $266.0M | ||
| Q3 24 | $104.8M | $261.0M | ||
| Q2 24 | $87.2M | $267.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-108.0M | ||
| Q3 25 | $-47.2M | $13.0M | ||
| Q2 25 | $-48.0M | $-26.0M | ||
| Q1 25 | $-59.4M | $-7.0M | ||
| Q4 24 | $-74.9M | $26.0M | ||
| Q3 24 | $-64.6M | $18.0M | ||
| Q2 24 | $-79.3M | $26.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 25.3% | ||
| Q2 25 | — | 19.4% | ||
| Q1 25 | — | 18.6% | ||
| Q4 24 | — | 19.2% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | — | 21.7% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -0.3% | ||
| Q3 25 | -27.0% | 7.1% | ||
| Q2 25 | -24.5% | -1.9% | ||
| Q1 25 | -46.9% | -5.3% | ||
| Q4 24 | -61.1% | -3.0% | ||
| Q3 24 | -59.8% | -3.1% | ||
| Q2 24 | -89.5% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -37.2% | ||
| Q3 25 | -27.6% | 4.8% | ||
| Q2 25 | -32.0% | -9.9% | ||
| Q1 25 | -48.9% | -2.8% | ||
| Q4 24 | -63.1% | 9.8% | ||
| Q3 24 | -61.7% | 6.9% | ||
| Q2 24 | -91.0% | 9.7% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-1.22 | ||
| Q3 25 | $-0.94 | $-0.08 | ||
| Q2 25 | $-0.97 | $-0.36 | ||
| Q1 25 | $-1.22 | $-0.12 | ||
| Q4 24 | $-1.54 | $0.22 | ||
| Q3 24 | $-1.34 | $0.15 | ||
| Q2 24 | $-1.67 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $436.0M |
| Total DebtLower is stronger | $70.0M | $209.0M |
| Stockholders' EquityBook value | — | $614.0M |
| Total Assets | $713.6M | $1.6B |
| Debt / EquityLower = less leverage | — | 0.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $436.0M | ||
| Q3 25 | $325.3M | $168.0M | ||
| Q2 25 | $303.0M | $155.0M | ||
| Q1 25 | $300.9M | $158.0M | ||
| Q4 24 | $315.4M | $201.0M | ||
| Q3 24 | $327.3M | $214.0M | ||
| Q2 24 | $315.7M | $251.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $209.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $467.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $614.0M | ||
| Q3 25 | $73.7M | $762.0M | ||
| Q2 25 | $73.1M | $528.0M | ||
| Q1 25 | $53.2M | $563.0M | ||
| Q4 24 | $57.0M | $641.0M | ||
| Q3 24 | $92.9M | $982.0M | ||
| Q2 24 | $102.9M | $961.0M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.6B | ||
| Q3 25 | $669.3M | $2.1B | ||
| Q2 25 | $639.8M | $1.9B | ||
| Q1 25 | $596.7M | $1.9B | ||
| Q4 24 | $568.5M | $2.0B | ||
| Q3 24 | $561.5M | $2.4B | ||
| Q2 24 | $548.2M | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.73× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $489.0M |
| Free Cash FlowOCF − Capex | — | $483.0M |
| FCF MarginFCF / Revenue | — | 166.6% |
| Capex IntensityCapex / Revenue | — | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $446.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $489.0M | ||
| Q3 25 | $1.0M | $21.0M | ||
| Q2 25 | $-32.4M | $8.0M | ||
| Q1 25 | $-43.4M | $-38.0M | ||
| Q4 24 | $-26.2M | $4.0M | ||
| Q3 24 | $-18.6M | $-21.0M | ||
| Q2 24 | $-30.1M | $-7.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $483.0M | ||
| Q3 25 | $988.0K | $17.0M | ||
| Q2 25 | $-32.4M | $-4.0M | ||
| Q1 25 | $-43.7M | $-50.0M | ||
| Q4 24 | $-26.2M | $-13.0M | ||
| Q3 24 | $-18.7M | $-41.0M | ||
| Q2 24 | $-30.2M | $-16.0M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 166.6% | ||
| Q3 25 | 0.6% | 6.3% | ||
| Q2 25 | -21.6% | -1.5% | ||
| Q1 25 | -36.0% | -20.2% | ||
| Q4 24 | -22.1% | -4.9% | ||
| Q3 24 | -17.9% | -15.7% | ||
| Q2 24 | -34.6% | -6.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 4.6% | ||
| Q1 25 | 0.3% | 4.9% | ||
| Q4 24 | 0.0% | 6.4% | ||
| Q3 24 | 0.1% | 7.7% | ||
| Q2 24 | 0.1% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.62× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | -1.17× | ||
| Q2 24 | — | -0.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
KODK
| Segment Continuing Operations | $195.0M | 67% |
| Advanced Materials And Chemicals | $85.0M | 29% |
| Other | $7.0M | 2% |
| All Other | $3.0M | 1% |
